Ibuprofen Sodium side effects: what 42,574 FDA adverse event reports show
Drug class
Nonsteroidal Anti-inflammatory Drug
Who reports
42,574 reports · 40% serious · 1,254 with death outcome · 70% female
Used for
Carefully consider the potential benefits and risks of ibuprofen tablets and other treatment options before deciding to use ibuprofen. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Ibuprofen tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis.
What it is
DESCRIPTION Ibuprofen tablets USP contain the active ingredient ibuprofen, which is (±) - 2 - ( p - isobutylphenyl) propionic acid. Ibuprofen is a white to off-white, crystalline powder with a.
Boxed warning
Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [see Warnings and Precautions ].
Causality screen of the 40 strongest signals
What the badges mean
- Labeled — boxed warning The term (or its clinical synonym) appears in the FDA boxed warning: causality is regulator-recognised and considered serious.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,144 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Swollen joint count | 32 | 73.5 50.7–106.6ROR 73.6 · calibrated p 2e-6 ✓ | 61.7 EB05 45.8 · IC025 +4.4 3/3 methods agree vs other NSAIDs: PRR 4.7 (3.3–6.8) | Not in label — unassessed | serious n=32 · ♀ 100% (drug 70%) · 100% clinician | not reported in cached trials |
| Grip strength | 26 | 62.1 41.3–93.4ROR 62.1 · calibrated p 8e-6 ✓ | 53.1 EB05 38.1 · IC025 +4.1 3/3 methods agree vs other NSAIDs: PRR 3.1 (2.1–4.6) | Not in label — unassessed | serious n=26 · 100% clinician | not reported in cached trials |
| Product coating issue | 83 | 43.6 34.9–54.6ROR 43.7 · calibrated p 4e-5 ✓ | 39.8 EB05 33.1 · IC025 +4.7 3/3 methods agree vs other NSAIDs: PRR 197.1 (121.0–321.1) | Reporting / coding artifact | 100% consumer | not reported in cached trials |
| Product difficult to swallow | 61 | 31.0 23.9–40.1ROR 31.0 · calibrated p 3e-4 ✓ | 28.9 EB05 23.3 · IC025 +4.1 3/3 methods agree vs other NSAIDs: only this drug | Reporting / coding artifact | 100% consumer | not reported in cached trials |
| Poor quality drug administered | 357 | 28.3 25.4–31.4ROR 28.5 · calibrated p 4e-4 ✓ | 26.7 EB05 24.5 · IC025 +4.5 3/3 methods agree vs other NSAIDs: PRR 17.7 (15.7–19.9) | Not in label — unassessed | serious n=42 · 94% consumer | not reported in cached trials |
| C-reactive protein | 40 | 22.7 16.5–31.1ROR 22.7 · calibrated p 0.001 ✓ | 21.5 EB05 16.4 · IC025 +3.6 3/3 methods agree vs other NSAIDs: PRR 0.5 (0.4–0.7) | Lab value / disease marker | serious n=40 · ♀ 100% (drug 70%) · 100% clinician | not reported in cached trials |
| Foreign body | 172 | 21.8 18.7–25.4ROR 21.9 · calibrated p 0.001 ✓ | 20.9 EB05 18.4 · IC025 +4.1 3/3 methods agree vs other NSAIDs: PRR 16.8 (14.1–20.0) | Not in label — unassessed | serious n=28 · 100% consumer | NCT00346216: 1/7,933 (0.0%) on Ibuprofen Sodium (serious AE) |
| Foreign body in respiratory tract | 56 | 21.7 16.6–28.4ROR 21.7 · calibrated p 0.002 ✓ | 20.7 EB05 16.5 · IC025 +3.7 3/3 methods agree vs other NSAIDs: PRR 46.7 (32.3–67.4) | Not in label — unassessed | 100% consumer | not reported in cached trials |
| Deep vein thrombosis postoperative | 80 | 20.9 16.7–26.1ROR 20.9 · calibrated p 0.002 ✓ | 20.0 EB05 16.6 · IC025 +3.8 3/3 methods agree vs other NSAIDs: PRR 0.5 (0.4–0.6) | Not in label — unassessed | serious n=80 · ♀ 100% (drug 70%) · 100% clinician | not reported in cached trials |
| Reaction to drug excipients | 75 | 17.3 13.8–21.8ROR 17.3 · calibrated p 0.004 ✓ | 16.7 EB05 13.7 · IC025 +3.5 3/3 methods agree vs other NSAIDs: only this drug | Not in label — unassessed | 86% consumer | not reported in cached trials |
| Drug effective for unapproved indication | 939 | 16.3 15.3–17.4ROR 16.7 · calibrated p 0.004 ✓ | 15.8 EB05 15.0 · IC025 +3.9 3/3 methods agree vs other NSAIDs: PRR 11.1 (10.3–11.9) | Labeled (related wording) related wording | 100% consumer | not reported in cached trials |
| Drug effect delayed | 146 | 16.1 13.7–19.0ROR 16.2 · calibrated p 0.005 ✓ | 15.6 EB05 13.6 · IC025 +3.6 3/3 methods agree vs other NSAIDs: PRR 18.4 (15.2–22.3) | Reporting / coding artifact | 100% consumer | not reported in cached trials |
| Retinitis | 50 | 15.2 11.4–20.1ROR 15.2 · calibrated p 0.008 ✓ | 14.6 EB05 11.4 · IC025 +3.2 3/3 methods agree vs other NSAIDs: PRR 0.7 (0.5–0.9) | Not in label — unassessed | serious n=50 · ♀ 100% (drug 70%) · 100% clinician | not reported in cached trials |
| Adjustment disorder with depressed mood | 59 | 14.8 11.4–19.2ROR 14.8 · calibrated p 0.008 ✓ | 14.3 EB05 11.4 · IC025 +3.3 3/3 methods agree vs other NSAIDs: PRR 0.4 (0.3–0.5) | Not in label — unassessed | serious n=58 · ♀ 100% (drug 70%) · 100% clinician | not reported in cached trials |
| Product shape issue | 27 | 14.6 10.0–21.4ROR 14.6 · calibrated p 0.010 ✓ | 13.8 EB05 9.7 · IC025 +2.9 3/3 methods agree vs other NSAIDs: only this drug | Reporting / coding artifact | 100% consumer | not reported in cached trials |
| Product commingling | 30 | 14.5 10.1–20.8ROR 14.5 · calibrated p 0.010 ✓ | 13.7 EB05 9.8 · IC025 +2.9 3/3 methods agree vs other NSAIDs: PRR 54.8 (32.4–92.6) | Reporting / coding artifact | 100% consumer | not reported in cached trials |
| Facet joint syndrome | 87 | 13.9 11.3–17.3ROR 14.0 · calibrated p 0.010 ✓ | 13.5 EB05 11.2 · IC025 +3.3 3/3 methods agree vs other NSAIDs: PRR 0.4 (0.3–0.5) | Not in label — unassessed | serious n=86 · ♀ 100% (drug 70%) · 100% clinician | NCT00346216: 1/7,933 (0.0%) on Ibuprofen Sodium (serious AE) |
| Blood pressure diastolic abnormal | 70 | 13.8 10.8–17.4ROR 13.8 · calibrated p 0.011 ✓ | 13.3 EB05 10.8 · IC025 +3.2 3/3 methods agree vs other NSAIDs: PRR 1.5 (1.2–1.9) | Lab value / disease marker | serious n=63 · 100% clinician | not reported in cached trials |
| Blood pressure systolic abnormal | 67 | 13.6 10.7–17.3ROR 13.6 · calibrated p 0.011 ✓ | 13.1 EB05 10.6 · IC025 +3.2 3/3 methods agree vs other NSAIDs: PRR 1.6 (1.3–2.1) | Lab value / disease marker | serious n=62 · 100% clinician | NCT00346216: 1/7,933 (0.0%) on Ibuprofen Sodium (serious AE) |
| Lupus vulgaris | 32 | 13.6 9.6–19.3ROR 13.6 · calibrated p 0.013 ✓ | 12.8 EB05 9.3 · IC025 +2.9 3/3 methods agree vs other NSAIDs: PRR 0.3 (0.2–0.5) | Not in label — unassessed | serious n=32 · ♀ 100% (drug 70%) · 100% clinician | not reported in cached trials |
| Dislocation of vertebra | 57 | 12.9 9.9–16.8ROR 12.9 · calibrated p 0.014 ✓ | 12.4 EB05 9.8 · IC025 +3.1 3/3 methods agree vs other NSAIDs: PRR 0.4 (0.3–0.5) | Not in label — unassessed | serious n=57 · ♀ 100% (drug 70%) · 100% clinician | not reported in cached trials |
| X-ray abnormal | 44 | 12.4 9.2–16.7ROR 12.4 · calibrated p 0.017 ✓ | 11.8 EB05 9.0 · IC025 +2.9 3/3 methods agree vs other NSAIDs: PRR 0.4 (0.3–0.5) | Lab value / disease marker | serious n=44 · ♀ 100% (drug 70%) · 100% clinician | not reported in cached trials |
| Swollen joint count increased | 66 | 10.6 8.3–13.5ROR 10.6 · calibrated p 0.028 ✓ | 10.1 EB05 8.2 · IC025 +2.9 3/3 methods agree vs other NSAIDs: PRR 0.3 (0.2–0.4) | Lab value / disease marker | serious n=66 · ♀ 100% (drug 70%) · 100% clinician | not reported in cached trials |
| Skin papilloma | 79 | 9.9 7.9–12.3ROR 9.9 · calibrated p 0.036 ✓ | 9.4 EB05 7.8 · IC025 +2.8 3/3 methods agree vs other NSAIDs: PRR 18.1 (14.0–23.5) | Not in label — unassessed | serious n=73 · ♀ 100% (drug 70%) | not reported in cached trials |
| Porphyria acute | 27 | 9.8 6.7–14.3ROR 9.8 · calibrated p 0.041 ✓ | 8.9 EB05 6.2 · IC025 +2.4 3/3 methods agree vs other NSAIDs: PRR 0.6 (0.4–0.8) | Not in label — unassessed | serious n=27 · ♀ 100% (drug 70%) · 100% clinician | not reported in cached trials |
| Peripheral venous disease | 77 | 9.7 7.7–12.1ROR 9.7 · calibrated p 0.038 ✓ | 9.2 EB05 7.6 · IC025 +2.8 3/3 methods agree vs other NSAIDs: PRR 0.4 (0.4–0.5) | Not in label — unassessed | serious n=76 · ♀ 100% (drug 70%) · 100% clinician | NCT00346216: 1/7,992 (0.0%) on Ibuprofen Sodium (serious AE) |
| Product used for unknown indication | 24 | 9.6 6.4–14.4ROR 9.6 · calibrated p 0.044 ✓ | 8.6 EB05 5.9 · IC025 +2.3 3/3 methods agree vs other NSAIDs: only this drug | Reporting / coding artifact | – | not reported in cached trials |
| Rheumatic fever | 83 | 9.5 7.7–11.8ROR 9.5 · calibrated p 0.040 ✓ | 9.1 EB05 7.5 · IC025 +2.8 3/3 methods agree vs other NSAIDs: PRR 0.3 (0.2–0.3) | Likely indication confounding shares a disease stem with the indications wording | serious n=83 · ♀ 100% (drug 70%) · 100% clinician | not reported in cached trials |
| Foreign body in throat | 56 | 9.2 7.1–12.0ROR 9.2 · calibrated p 0.046 ✓ | 8.7 EB05 6.9 · IC025 +2.6 3/3 methods agree vs other NSAIDs: PRR 12.1 (9.1–16.3) | Not in label — unassessed | serious n=55 · 100% consumer | not reported in cached trials |
| Biliary dyskinesia | 31 | 9.0 6.3–12.9ROR 9.0 · calibrated p 0.052 | 8.2 EB05 5.9 · IC025 +2.4 3/3 methods agree vs other NSAIDs: PRR 1.3 (0.9–1.9) | Not in label — unassessed | serious n=31 · ♀ 100% (drug 70%) · 100% consumer | NCT00346216: 1/7,992 (0.0%) on Ibuprofen Sodium (serious AE) |
| Product taste abnormal | 237 | 8.8 7.8–10.0ROR 8.9 · calibrated p 0.049 ✓ | 8.6 EB05 7.7 · IC025 +2.9 3/3 methods agree vs other NSAIDs: PRR 6.3 (5.5–7.2) | Reporting / coding artifact | serious n=35 · 94% consumer | not reported in cached trials |
| Pre-existing condition improved | 105 | 8.3 6.9–10.1ROR 8.3 · calibrated p 0.061 | 8.0 EB05 6.8 · IC025 +2.7 3/3 methods agree vs other NSAIDs: PRR 1.9 (1.5–2.3) | Not in label — unassessed | serious n=17 · 83% consumer | not reported in cached trials |
| Bone erosion | 57 | 8.0 6.2–10.4ROR 8.0 · calibrated p 0.070 | 7.6 EB05 6.0 · IC025 +2.5 3/3 methods agree vs other NSAIDs: PRR 0.6 (0.5–0.8) | Not in label — unassessed | serious n=55 · ♀ 100% (drug 70%) · 100% clinician | NCT00346216: 1/7,933 (0.0%) on Ibuprofen Sodium (serious AE) |
| Product size issue | 84 | 7.9 6.4–9.8ROR 7.9 · calibrated p 0.072 | 7.5 EB05 6.3 · IC025 +2.5 3/3 methods agree vs other NSAIDs: PRR 46.9 (34.7–63.4) | Reporting / coding artifact | serious n=30 · 100% consumer | not reported in cached trials |
| C-reactive protein abnormal | 99 | 7.7 6.3–9.4ROR 7.7 · calibrated p 0.077 | 7.4 EB05 6.2 · IC025 +2.5 3/3 methods agree vs other NSAIDs: PRR 0.3 (0.3–0.4) | Lab value / disease marker | serious n=98 · ♀ 100% (drug 70%) · 100% clinician | not reported in cached trials |
| Duodenal ulcer perforation | 113 | 7.7 6.4–9.2ROR 7.7 · calibrated p 0.077 | 7.4 EB05 6.3 · IC025 +2.6 3/3 methods agree vs other NSAIDs: PRR 0.2 (0.2–0.2) | Labeled — boxed warning synonym match | serious PRR 11.0 · ♀ 100% (drug 70%) · 100% clinician | NCT00346216: 2/7,933 (0.0%) on Ibuprofen Sodium (serious AE) |
| Therapeutic product effect variable | 57 | 7.4 5.7–9.7ROR 7.5 · calibrated p 0.087 | 7.0 EB05 5.6 · IC025 +2.4 3/3 methods agree vs other NSAIDs: PRR 112.8 (70.0–181.7) | Reporting / coding artifact | 100% consumer | not reported in cached trials |
| Drug effect incomplete | 537 | 7.3 6.7–7.9ROR 7.3 · calibrated p 0.086 | 7.1 EB05 6.6 · IC025 +2.7 3/3 methods agree vs other NSAIDs: PRR 4.3 (4.0–4.7) | Reporting / coding artifact | serious PRR 4.7 · 88% consumer | not reported in cached trials |
| Rheumatoid factor positive | 84 | 7.3 5.9–9.0ROR 7.3 · calibrated p 0.092 | 6.9 EB05 5.8 · IC025 +2.4 3/3 methods agree vs other NSAIDs: PRR 0.3 (0.2–0.3) | Lab value / disease marker | serious n=84 · ♀ 100% (drug 70%) · 100% clinician | not reported in cached trials |
| Oral discomfort | 200 | 7.2 6.2–8.2ROR 7.2 · calibrated p 0.093 | 7.0 EB05 6.2 · IC025 +2.6 3/3 methods agree vs other NSAIDs: PRR 3.3 (2.9–3.8) | Not in label — unassessed | serious n=40 · 88% consumer | not reported in cached trials |
Trial evidence (ClinicalTrials.gov)
✓ Trial adverse-event data found on ClinicalTrials.gov
Largest completed trials with posted results that list Ibuprofen Sodium as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (7 of 40 signal terms matched).
- NCT00346216 — Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen (N=24081, PHASE4; 1238 AE terms posted; arms: Celecoxib; Ibuprofen; Naproxen)
- NCT01789606 — Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet (N=1083, PHASE3; 60 AE terms posted; arms: Compliance Arm)
Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Drug ineffective (drug did not work) | 6,831 | 2.6 2.5–2.6ROR 2.9 · calibrated p 0.673 | 2.6 EB05 2.5 · IC025 +1.3 3/3 methods agree vs other NSAIDs: PRR 1.6 (1.6–1.7) | Reporting / coding artifact | serious PRR 2.2 · 84% consumer | not reported in cached trials |
| Fatigue (tiredness) | 2,710 | 1.7 1.7–1.8ROR 1.8 · calibrated p 0.811 | 1.7 EB05 1.7 · IC025 +0.7 vs other NSAIDs: PRR 0.8 (0.7–0.8) | Not in label — unassessed | serious PRR 2.7 | NCT00346216: 2/7,992 (0.0%) on Ibuprofen Sodium (serious AE) |
| Nausea | 2,703 | 1.7 1.6–1.8ROR 1.7 · calibrated p 0.791 | 1.7 EB05 1.6 · IC025 +0.7 vs other NSAIDs: PRR 0.8 (0.8–0.9) | Labeled adverse reaction exact term | serious PRR 2.6 | NCT00346216: 3/7,992 (0.0%) on Ibuprofen Sodium (serious AE) |
| Headache | 2,577 | 2.0 2.0–2.1ROR 2.1 · calibrated p 0.996 | 2.0 EB05 2.0 · IC025 +1.0 vs other NSAIDs: PRR 0.9 (0.9–0.9) | Labeled adverse reaction exact term | serious PRR 3.0 | NCT00346216: 6/7,992 (0.1%) on Ibuprofen Sodium (serious AE) |
| Pain | 2,492 | 2.0 1.9–2.1ROR 2.1 · calibrated p 0.976 | 2.0 EB05 1.9 · IC025 +0.9 vs other NSAIDs: PRR 0.7 (0.7–0.8) | Labeled — boxed warning exact term | serious PRR 2.9 | NCT00346216: 7/7,992 (0.1%) on Ibuprofen Sodium (serious AE) |
| Diarrhoea (diarrhea) | 1,805 | 1.4 1.3–1.4ROR 1.4 · calibrated p 0.575 | 1.4 EB05 1.3 · IC025 +0.4 vs other NSAIDs: PRR 0.7 (0.7–0.7) | Labeled adverse reaction exact term | serious PRR 1.9 | NCT00346216: 8/7,992 (0.1%) on Ibuprofen Sodium (serious AE) |
| Product use in unapproved indication | 1,746 | 3.5 3.4–3.7ROR 3.6 · calibrated p 0.451 | 3.5 EB05 3.4 · IC025 +1.7 3/3 methods agree vs other NSAIDs: PRR 1.9 (1.8–2.0) | Reporting / coding artifact | serious PRR 2.1 · 85% consumer | not reported in cached trials |
| Dizziness | 1,742 | 1.7 1.6–1.8ROR 1.8 · calibrated p 0.803 | 1.7 EB05 1.7 · IC025 +0.7 vs other NSAIDs: PRR 0.8 (0.8–0.8) | Labeled adverse reaction exact term | serious PRR 2.4 | NCT00346216: 5/7,992 (0.1%) on Ibuprofen Sodium (serious AE) |
| Arthralgia (joint pain) | 1,669 | 2.0 1.9–2.1ROR 2.0 · calibrated p 0.959 | 2.0 EB05 1.9 · IC025 +0.9 vs other NSAIDs: PRR 0.6 (0.6–0.7) | Not in label — unassessed | serious PRR 3.4 | NCT00346216: 33/7,992 (0.4%) on Ibuprofen Sodium (serious AE) |
| Off label use (used outside approved label) | 1,473 | 0.8 0.8–0.9ROR 0.8 · calibrated p 0.201 | 0.8 EB05 0.8 · IC025 -0.3 PRR-only: not supported by EBGM or IC vs other NSAIDs: PRR 0.6 (0.6–0.6) | Reporting / coding artifact | serious PRR 1.5 | not reported in cached trials |
| Dyspnoea (shortness of breath) | 1,441 | 1.3 1.2–1.3ROR 1.3 · calibrated p 0.484 | 1.3 EB05 1.2 · IC025 +0.2 vs other NSAIDs: PRR 0.6 (0.5–0.6) | Not in label — unassessed | serious PRR 1.8 | NCT00346216: 24/7,992 (0.3%) on Ibuprofen Sodium (serious AE) |
| Vomiting | 1,398 | 1.5 1.4–1.5ROR 1.5 · calibrated p 0.632 | 1.5 EB05 1.4 · IC025 +0.5 vs other NSAIDs: PRR 0.6 (0.6–0.6) | Labeled adverse reaction exact term | serious PRR 2.1 | NCT00346216: 7/7,992 (0.1%) on Ibuprofen Sodium (serious AE) |
| Malaise (feeling unwell) | 1,356 | 1.5 1.4–1.6ROR 1.5 · calibrated p 0.666 | 1.5 EB05 1.5 · IC025 +0.5 vs other NSAIDs: PRR 0.8 (0.8–0.8) | Not in label — unassessed | serious PRR 2.0 | NCT00346216: 1/7,992 (0.0%) on Ibuprofen Sodium (serious AE) |
| Abdominal discomfort | 1,308 | 3.9 3.7–4.1ROR 4.0 · calibrated p 0.384 | 3.8 EB05 3.7 · IC025 +1.9 3/3 methods agree vs other NSAIDs: PRR 1.0 (1.0–1.1) | Not in label — unassessed | serious PRR 3.8 · 76% consumer | NCT00346216: 1/7,992 (0.0%) on Ibuprofen Sodium (serious AE) |
| Rash | 1,255 | 1.4 1.4–1.5ROR 1.4 · calibrated p 0.601 | 1.4 EB05 1.4 · IC025 +0.4 vs other NSAIDs: PRR 0.6 (0.6–0.6) | Labeled adverse reaction exact term | serious PRR 2.2 | NCT00346216: 1/8,030 (0.0%) on Ibuprofen Sodium (serious AE) |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Swollen joint count — n=32, PRR 73.5
- Grip strength — n=26, PRR 62.1
- Poor quality drug administered — n=357, PRR 28.3
- Foreign body — n=172, PRR 21.8 (also seen in trial arm)
- Foreign body in respiratory tract — n=56, PRR 21.7
- Deep vein thrombosis postoperative — n=80, PRR 20.9
- Reaction to drug excipients — n=75, PRR 17.3
- Retinitis — n=50, PRR 15.2
- Adjustment disorder with depressed mood — n=59, PRR 14.8
- Facet joint syndrome — n=87, PRR 13.9 (also seen in trial arm)
✓ A hand-written Bradford Hill causality assessment exists for this drug: Ibuprofen (NSAIDs) ↔ Gastrointestinal bleeding.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Ibuprofen Sodium?
In FDA FAERS, the most frequently co-reported reaction terms for Ibuprofen Sodium are fatigue, nausea, headache, pain, diarrhoea, dizziness. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Ibuprofen Sodium have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [see Warnings and Precautions ].
Do FAERS signals prove that Ibuprofen Sodium causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 00872852-680a-41b3-901b-b991b12a176d, effective 20250214; matched on
openfda.generic_name.exact:"IBUPROFEN") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,184 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
IBUPROFEN, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.